Bioneer Corporation
Bioneer Corporation engages in the biotechnology research products, molecular diagnosis, drugs, and probiotics businesses in South Korea. The company offers PCR and RT-PCR, real-time PCR, RNAi, chemicals, plastic consumables, and buffer solutions; and sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher, electrophoresis, genome-wide functional analys… Read more
Bioneer Corporation - Asset Resilience Ratio
Bioneer Corporation (064550) has an Asset Resilience Ratio of 14.92% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Bioneer Corporation's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Bioneer Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩56.17 Billion | 14.92% |
| Total Liquid Assets | ₩56.17 Billion | 14.92% |
Asset Resilience Insights
- Moderate Liquidity: Bioneer Corporation has 14.92% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Bioneer Corporation Industry Peers by Asset Resilience Ratio
Compare Bioneer Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Macrogen Inc
KQ:038290 |
Biotechnology & Medical Research | 3.56% |
|
Panagene Inc
KQ:046210 |
Biotechnology & Medical Research | 0.14% |
|
Cell Biotech Co. Ltd
KQ:049960 |
Biotechnology & Medical Research | 54.84% |
|
MEDIPOST Co. Ltd
KQ:078160 |
Biotechnology & Medical Research | 0.72% |
|
Biotoxtech Co. Ltd
KQ:086040 |
Biotechnology & Medical Research | 7.17% |
|
Peptron Inc
KQ:087010 |
Biotechnology & Medical Research | 57.41% |
|
Hadasit Bio
TA:HDST |
Biotechnology & Medical Research | 57.00% |
|
Pluristem
TA:PSTI |
Biotechnology & Medical Research | 48.26% |
Annual Asset Resilience Ratio for Bioneer Corporation (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Bioneer Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 16.33% | ₩54.24 Billion | ₩332.19 Billion | +2.61pp |
| 2023-12-31 | 13.72% | ₩43.29 Billion | ₩315.49 Billion | -13.07pp |
| 2022-12-31 | 26.79% | ₩80.03 Billion | ₩298.74 Billion | -3.57pp |
| 2021-12-31 | 30.36% | ₩79.68 Billion | ₩262.42 Billion | -0.93pp |
| 2020-12-31 | 31.29% | ₩59.82 Billion | ₩191.17 Billion | +0.55pp |
| 2019-12-31 | 30.74% | ₩25.24 Billion | ₩82.10 Billion | +23.94pp |
| 2018-12-31 | 6.80% | ₩4.81 Billion | ₩70.81 Billion | -9.04pp |
| 2017-12-31 | 15.84% | ₩9.29 Billion | ₩58.70 Billion | +8.17pp |
| 2016-12-31 | 7.67% | ₩4.89 Billion | ₩63.71 Billion | +7.60pp |
| 2015-12-31 | 0.07% | ₩50.00 Million | ₩71.99 Billion | -0.13pp |
| 2014-12-31 | 0.20% | ₩135.68 Million | ₩67.36 Billion | -0.33pp |
| 2013-12-31 | 0.53% | ₩369.29 Million | ₩69.93 Billion | -0.59pp |
| 2012-12-31 | 1.11% | ₩758.82 Million | ₩68.13 Billion | +0.26pp |
| 2011-12-31 | 0.86% | ₩605.70 Million | ₩70.63 Billion | -- |